Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease

BACKGROUND: Many pediatric patients with inflammatory bowel disease (IBD) lose response to infliximab (IFX) within the first year, and achieving a minimal target IFX trough concentration is associated with higher remission rates and longer durability. Population pharmacokinetic (PK) modeling can pre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Inflamm Bowel Dis
Main Authors: Bauman, Laura E, Xiong, Ye, Mizuno, Tomoyuki, Minar, Philip, Fukuda, Tsuyoshi, Dong, Min, Rosen, Michael J, Vinks, Alexander A
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7171445/
https://ncbi.nlm.nih.gov/pubmed/31287855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izz143
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados